tyrosine has been researched along with hirudin in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.08) | 18.7374 |
| 1990's | 15 (31.25) | 18.2507 |
| 2000's | 18 (37.50) | 29.6817 |
| 2010's | 13 (27.08) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, S; Fernando, PH; Liu, MC; Nakajima, H; Nakatsu, S; Sakakibara, Y; Suiko, M | 1 |
| Betz, A; Hofsteenge, J; Stone, SR | 2 |
| Donella-Deana, A; Hofsteenge, J; Pinna, LA; Stone, SR | 1 |
| Bourdon, P; Chao, BH; Jablonski, JA; Maraganore, JM | 1 |
| Benatti, L; de Taxis du Poet, P; Nitti, G; Sarmientos, P; Scacheri, E; Valsasina, B | 1 |
| Carperos, VE; Maraganore, JM; Ravichandran, KG; Skrzypczak-Jankun, E; Tulinsky, A; Westbrook, M | 1 |
| Carvallo, D; Degryse, E; Huttner, WB; Niehrs, C | 1 |
| Gravem, K; Jakobsen, E; Kierulf, P; Ly, B | 1 |
| Hayashi, H; Kobashi, K; Komatsu, Y; Misawa, S; Morikawa, T; Muramatsu, R; Nukui, E; Okayama, T; Sukesada, A; Wada, K | 1 |
| Grütter, MG; Priestle, JP; Rahuel, J; Rink, H; Tones, M | 1 |
| Druker, BJ; Handa, M; Ikeda, Y; Miyakawa, Y; Miyazaki, H; Oda, A; Ohashi, H | 1 |
| Hayashi, H; Kobashi, K; Komatsu, Y; Morikawa, T; Muramatsu, R; Nukui, E; Okayama, T | 1 |
| Scheraga, HA; Thannhauser, TW | 1 |
| Hayashi, H; Komatsu, Y | 1 |
| De Filippis, V; Di Cera, E; Fontana, A; Quarzago, D; Vindigni, A | 1 |
| Hetzer, R; Koster, A; Kuppe, H; Loebe, M; Mertzlufft, F | 1 |
| Bassand, JP | 1 |
| Caputo, RP; Esente, P; Giambartolomei, A; Reger, M; Simons, A; Wagner, S | 1 |
| Carrozza, JP; Cohen, DJ; Pinto, DS; Sperling, RT; Tu, TM | 1 |
| Farrell, DH; Lovely, RS; Moaddel, M | 1 |
| Cochran, K; DeMartini, TJ; Grassman, ED; Lewis, BE; Leya, F; O Brien, J; Steen, LH | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Allie, AA; Allie, DE; Allie, SE; Barker, EA; Chaisson, G; Fail, PS; Hebert, CJ; Keller, VA; Khan, MA; Khan, MH; Lirtzman, MD; McElderry, MW; Mitran, EV; Stagg, SJ; Vivekananthan, K; Walker, CM; Wyatt, CH | 1 |
| Bhatt, DL; Duffy, B | 1 |
| De Filippis, V; Fontana, A; Frasson, R | 1 |
| Braun, S; Dietrich, W; Eicken, A; Kostolny, M; Lange, R; Schreiber, C | 1 |
| Liu, CC; Schultz, PG | 1 |
| Choe, H; Farzan, M | 1 |
| Ligon, RW; Markwell, SJ; Mishkel, GJ; Moore, AL | 1 |
| Brustad, E; Liu, CC; Liu, W; Schultz, PG | 1 |
| Bradbury, AR; Heegaard, NH; Lassen, KS; Rehfeld, JF | 1 |
| Baldus, S; Bonacci, G; Freeman, BA; Klinke, A; Lau, D; Meinertz, T; Rudolph, TK; Rudolph, V; Schopfer, FJ; Szöcs, K | 1 |
| Biondi-Zoccai, G; Bolognese, L; Briguori, C; Campo, G; Danzi, GB; Hamm, C; King, SB; Moliterno, DJ; Okmen, E; Saia, F; Tebaldi, M; ten Berg, J; Topol, EJ; Valgimigli, M; van't Hof, AW | 1 |
| Briguori, C; Caccavale, M; D'Andrea, D; Focaccio, A; Golia, B; Librera, M; Ricciarelli, B; Tavano, D; Visconti, G | 1 |
| Brazier, JE; Fox, KA; Schwenkglenks, M; Szucs, TD | 1 |
| Moliterno, DJ | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Huang, Y; Mo, W; Song, H; Xu, Q; Yu, M; Zhang, Y; Zhao, B; Zhou, X | 1 |
| Heemskerk, JW; Lancé, MD; Lionikiene, AS; Mastenbroek, TG; Mutch, NJ; Swieringa, F; van der Meijden, PE; Whyte, CS | 1 |
| Cavender, MA; Faxon, DP | 1 |
| Chen, J; Chen, S; Guo, J; Han, Y; Jiang, D; Jiang, T; Jing, Q; Li, J; Li, Y; Liang, Z; Liu, H; Stone, GW; Su, X; Wang, Y; Xu, B; Yang, P; Zang, H; Zhao, X; Zheng, Y | 1 |
| Payne, RJ; Stone, MJ | 1 |
| He, Y; Jin, J; Li, J; Qian, D; Yu, S | 1 |
| Han, Y; Li, Y; Liang, Z; Liu, H; Ma, L; Stone, GW; Wang, D; Wang, J; Wang, S; Yang, L | 1 |
| Chen, SL; Chen, YD; Chen, YG; Cheng, XS; Ge, JB; Han, YL; Jiang, TM; Li, JL; Li, Y; Liang, ZY; Liu, HW; Liu, ML; Ma, LK; Ma, YT; Wang, G; Wang, HY; Xie, Q; Yang, BS; Zhao, X; Zheng, XQ | 1 |
| Bao, D; Chen, Y; Cong, H; Ding, S; Han, Y; Jia, S; Jing, Q; Li, J; Li, L; Li, Y; Liang, Z; Liu, B; Liu, H; Wang, H; Zhao, X | 1 |
| Barbosa Pereira, PJ; Maxwell, JWC; Payne, RJ; Ripoll-Rozada, J | 1 |
8 review(s) available for tyrosine and hirudin
| Article | Year |
|---|---|
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets.
Topics: Animals; Aspirin; Blood Platelets; Cell Line; DNA-Binding Proteins; Epinephrine; Hirudins; Humans; Janus Kinase 2; Mice; Milk Proteins; Neoplasm Proteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptors, Cytokine; Receptors, Thrombopoietin; Signal Transduction; STAT1 Transcription Factor; STAT2 Transcription Factor; STAT3 Transcription Factor; STAT5 Transcription Factor; STAT6 Transcription Factor; Thrombopoietin; Trans-Activators; Transfection; Tyrosine | 1996 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Complications; Drug Therapy, Combination; Eptifibatide; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Oligosaccharides; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Factors; Thrombocytopenia; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Thrombocytopenia; Tirofiban; Tyrosine | 2003 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Clopidogrel; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Recombinant Proteins; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Chemotherapy, Adjuvant; Hemorrhage; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Regression Analysis; Tirofiban; Tyrosine | 2010 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis.
Topics: Antithrombins; Cardiac Catheterization; Eptifibatide; Hirudins; Humans; Integrin alpha2; Myocardial Infarction; Peptide Fragments; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Tirofiban; Treatment Outcome; Tyrosine | 2015 |
7 trial(s) available for tyrosine and hirudin
| Article | Year |
|---|---|
Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recombinant Proteins; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase.
Topics: Aged; Animals; Antithrombins; Biological Availability; Cattle; Female; Fluorescent Antibody Technique; Hirudins; Humans; Male; Methylation; Middle Aged; Nitric Oxide; Peptide Fragments; Peroxidase; Recombinant Proteins; Spectrometry, Mass, Electrospray Ionization; Tyrosine; Vasodilation | 2008 |
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Retreatment; Thrombocytopenia; Tirofiban; Tyrosine | 2009 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2011 |
Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Topics: Aged; Antithrombins; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Tirofiban; Tyrosine | 2015 |
The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
Topics: Aged; Anticoagulants; Antithrombins; Chi-Square Distribution; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Emergency Treatment; Female; Hemorrhage; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Protective Factors; Recombinant Proteins; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cardiac Catheterization; China; Emergencies; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radial Artery; Recombinant Proteins; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Warfarin; Young Adult | 2017 |
33 other study(ies) available for tyrosine and hirudin
| Article | Year |
|---|---|
Post-translational modification of protein by tyrosine sulfation: active sulfate PAPS is the essential substrate for this modification.
Topics: Amino Acid Sequence; Animals; Cattle; Escherichia coli; Hirudins; Liver; Molecular Sequence Data; Phosphoadenosine Phosphosulfate; Protein Processing, Post-Translational; Recombinant Proteins; Sulfotransferases; Sulfuric Acids; Tyrosine | 1992 |
Interaction of the N-terminal region of hirudin with the active-site cleft of thrombin.
Topics: Amino Acid Sequence; Aspartic Acid; Binding Sites; Hirudins; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Protein Conformation; Recombinant Proteins; Structure-Activity Relationship; Threonine; Thrombin; Tyrosine; Valine | 1992 |
The effect of substituting phosphotyrosine for sulphotyrosine on the activity of hirudin.
Topics: Adenosine Triphosphate; Amino Acids; Binding Sites; Chromatography, Ion Exchange; Hirudins; Humans; Kinetics; Peptide Mapping; Phosphorylation; Phosphotyrosine; Protein-Tyrosine Kinases; Recombinant Proteins; Thrombin; Tyrosine | 1990 |
Structure-function relationships of hirulog peptide interactions with thrombin.
Topics: Amino Acid Sequence; Anions; Binding Sites; Binding, Competitive; Hirudins; Iodine; Molecular Sequence Data; Structure-Activity Relationship; Sulfates; Thrombin; Tyrosine | 1991 |
Production of the HV1 variant of hirudin by recombinant DNA methodology.
Topics: Amino Acid Sequence; Animals; Bacterial Outer Membrane Proteins; Baculoviridae; Base Sequence; Cells, Cultured; Cloning, Molecular; Escherichia coli; Genes, Synthetic; Genetic Vectors; Hirudins; Molecular Sequence Data; Moths; Phosphorylation; Promoter Regions, Genetic; Protein Processing, Post-Translational; Protein Sorting Signals; Recombinant Fusion Proteins; Recombinant Proteins; Tyrosine | 1991 |
Role of interactions involving C-terminal nonpolar residues of hirudin in the formation of the thrombin-hirudin complex.
Topics: Amino Acid Sequence; Binding Sites; Hirudins; Kinetics; Mutagenesis, Site-Directed; Phenylalanine; Proline; Protein Conformation; Thermodynamics; Thrombin; Tyrosine | 1991 |
Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.
Topics: Amino Acid Sequence; Binding Sites; Circular Dichroism; Crystallography; Hirudins; Humans; Hydrogen Bonding; Models, Molecular; Molecular Sequence Data; Peptide Fragments; Protein Conformation; Recombinant Proteins; Sulfur; Thrombin; Tyrosine; X-Ray Diffraction | 1991 |
Conversion of recombinant hirudin to the natural form by in vitro tyrosine sulfation. Differential substrate specificities of leech and bovine tyrosylprotein sulfotransferases.
Topics: Adrenal Medulla; Amino Acid Sequence; Animals; Carboxypeptidases; Cattle; Cholecystokinin; Hirudins; Kinetics; Leeches; Molecular Sequence Data; Peptide Fragments; Phosphoadenosine Phosphosulfate; Protein Processing, Post-Translational; Recombinant Proteins; Substrate Specificity; Sulfates; Sulfotransferases; Thrombin; Tyrosine | 1990 |
Characterization of soluble, FSF-stabilized fibrin complexes with special reference to the role of fibrinogen.
Topics: Calcium; Electrophoresis, Polyacrylamide Gel; Factor XIII; Fibrinogen; Glycine; Hirudins; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Iodine Isotopes; Molecular Conformation; Peptide Fragments; Radiometry; Scintillation Counting; Solubility; Thrombin; Tyrosine | 1974 |
Enzymic O-sulfation of tyrosine residues in hirudins by sulfotransferase from Eubacterium A-44.
Topics: Amino Acid Sequence; Antithrombins; Base Sequence; Eubacterium; Hirudins; Humans; Kinetics; Molecular Sequence Data; Oligodeoxyribonucleotides; Sulfates; Sulfotransferases; Tyrosine | 1994 |
Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms.
Topics: Amino Acid Sequence; Binding Sites; Crystallization; Crystallography, X-Ray; Electrochemistry; Fibrinogen; Hirudins; Humans; Hydrogen Bonding; Molecular Sequence Data; Molecular Structure; Protein Conformation; Structure-Activity Relationship; Sulfates; Thrombin; Tyrosine | 1993 |
Structure-activity studies on C-terminal hirudin peptides containing sulfated tyrosine residues.
Topics: Amino Acid Sequence; Antithrombins; Hirudins; Humans; Molecular Sequence Data; Structure-Activity Relationship; Sulfates; Tyrosine | 1996 |
State of aggregation of recombinant hirudin in solution under physiological conditions.
Topics: Animals; Chromatography, Gel; Hirudins; Leeches; Molecular Weight; Nitrobenzoates; Protein Conformation; Protein Folding; Recombinant Proteins; Sulfates; Tyrosine; Ultracentrifugation | 1996 |
Reevaluating the effects of tyrosine iodination of recombinant hirudin on its thrombin inhibition kinetics.
Topics: Amino Acid Sequence; Antithrombins; Chromatography, High Pressure Liquid; Hirudins; Humans; Iodine; Molecular Sequence Data; Recombinant Proteins; Thrombin; Tyrosine | 1997 |
Synthesis and characterization of more potent analogues of hirudin fragment 1-47 containing non-natural amino acids.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Animals; Arginine; Cattle; Circular Dichroism; Glycine; Hirudins; Humans; Molecular Sequence Data; Peptide Fragments; Phenylalanine; Serine; Spectrometry, Fluorescence; Thrombin; Tyrosine; Valine | 1998 |
Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant.
Topics: Cardiopulmonary Bypass; Drug Therapy, Combination; Female; Heart Valve Prosthesis Implantation; Heparin; Hirudins; Humans; Kidney Function Tests; Middle Aged; Mitral Valve; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Prosthesis Failure; Recombinant Proteins; Reoperation; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Topics: Aged; Aged, 80 and over; Anticoagulants; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Platelet Aggregation Inhibitors; Recombinant Proteins; Renal Insufficiency; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
Fibrinogen gamma' chain binds thrombin exosite II.
Topics: Amino Acid Sequence; Animals; Binding Sites; Binding, Competitive; Cell Line; DNA; Fibrinogen; Heparin; Hirudins; Humans; Kinetics; Mice; Molecular Sequence Data; Protein Binding; Protein Isoforms; Recombinant Proteins; Substrate Specificity; Thrombin; Transfection; Tyrosine | 2003 |
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Topics: Acute Disease; Aged; Angioplasty, Balloon; Anticoagulants; Feasibility Studies; Female; Follow-Up Studies; Hirudins; Humans; Ischemia; Leg; Male; Myocardial Ischemia; Peptide Fragments; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Thrombin; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
3-Nitrotyrosine as a spectroscopic probe for investigating protein protein interactions.
Topics: Amino Acid Substitution; Binding Sites; Energy Transfer; Fluorescence; Hirudins; Models, Molecular; Protein Binding; Protein Conformation; Protein Interaction Mapping; Structure-Activity Relationship; Thrombin; Tyrosine | 2006 |
Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies.
Topics: Antibodies; Anticoagulants; Aprotinin; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child; Drug Therapy, Combination; Heart Valve Prosthesis Implantation; Hemostatics; Heparin; Hirudins; Humans; Male; Mitral Valve; Phenprocoumon; Platelet Aggregation Inhibitors; Platelet Factor 4; Recombinant Proteins; Reoperation; Thrombocytopenia; Tirofiban; Tyrosine; Ventricular Outflow Obstruction | 2006 |
Recombinant expression of selectively sulfated proteins in Escherichia coli.
Topics: Amino Acyl-tRNA Synthetases; Bacterial Proteins; Codon, Nonsense; Escherichia coli; Hirudins; Protein Processing, Post-Translational; Recombinant Proteins; Thrombin; Tyrosine | 2006 |
Tyrosine sulfate trapped by amber.
Topics: Amino Acyl-tRNA Synthetases; Antibody Formation; Bacterial Proteins; Escherichia coli; Hirudins; Protein Binding; Protein Processing, Post-Translational; Recombinant Proteins; Tyrosine | 2006 |
Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Coronary Artery Disease; Costs and Cost Analysis; Drug Delivery Systems; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Length of Stay; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Peptide Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin.
Topics: Crystallography, X-Ray; Hirudins; Models, Molecular; Protein Conformation; Thrombin; Tyrosine | 2007 |
Microscale characterization of the binding specificity and affinity of a monoclonal antisulfotyrosyl IgG antibody.
Topics: Antibodies, Monoclonal; Antibody Affinity; Antibody Specificity; Complement C4; Electrophoresis, Capillary; Gastrins; Hirudins; Immunoglobulin G; Peptide Fragments; Protein Binding; Sincalide; Surface Plasmon Resonance; Tyrosine | 2008 |
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Female; Health Care Costs; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Models, Econometric; Myocardial Revascularization; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Quality-Adjusted Life Years; Recombinant Proteins; Survival Analysis; Tirofiban; Tyrosine; United Kingdom | 2011 |
Structural basis of RGD-hirudin binding to thrombin: Tyr3 and five C-terminal residues are crucial for inhibiting thrombin activity.
Topics: Binding Sites; Catalytic Domain; Hirudins; Models, Molecular; Molecular Docking Simulation; Pichia; Point Mutation; Protein Refolding; Surface Plasmon Resonance; Thrombin; Tyrosine | 2014 |
Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.
Topics: Blood Platelets; Crotalid Venoms; Fibrin; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Flow Cytometry; Hemostatics; Hirudins; Lectins, C-Type; Microscopy, Confocal; Oligopeptides; Phosphatidylserines; Protein Binding; Rheology; Shear Strength; Thrombin; Thrombosis; Tirofiban; Tissue Plasminogen Activator; Tyrosine; Urokinase-Type Plasminogen Activator | 2015 |
Can BRIGHT restore the glow of bivalirudin?
Topics: Antithrombins; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Tirofiban; Tyrosine | 2015 |
Homogeneous sulfopeptides and sulfoproteins: synthetic approaches and applications to characterize the effects of tyrosine sulfation on biochemical function.
Topics: Amino Acid Sequence; Binding Sites; Hirudins; HIV Infections; HIV-1; Humans; Magnetic Resonance Spectroscopy; Molecular Sequence Data; Peptides; Protein Processing, Post-Translational; Receptors, CCR3; Receptors, CCR5; Solid-Phase Synthesis Techniques; Sulfates; Tyrosine | 2015 |
[A large-scale, multicenter, retrospective study on efficacy of bivalirudin use during peri-percutaneous coronary intervention period for Chinese patients with coronary heart disease].
Topics: Aged; China; Coronary Disease; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Retrospective Studies; Stroke; Tirofiban; Tyrosine | 2016 |
Tyrosine-O-sulfation is a widespread affinity enhancer among thrombin interactors.
Topics: Amino Acid Sequence; Animals; Anticoagulants; Hirudins; Thrombin; Tyrosine | 2022 |